We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+109.07%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$510M
AUM Growth
+$233M
Cap. Flow
+$45.1M
Cap. Flow %
8.85%
Top 10 Hldgs %
42.94%
Holding
56
New
7
Increased
29
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$9.74M
2
OCUL icon
Ocular Therapeutix
OCUL
+$8.11M
3
FOCL
EDAP TMS S.A.
FOCL
+$6.97M
4
FLXN
Flexion Therapeutics, Inc.
FLXN
+$5.24M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.4M

Top Sells

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$8.04M
2
CYTK icon
Cytokinetics
CYTK
+$7.4M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$4.79M
4
THOR
Synthorx, Inc. Common Stock
THOR
+$2.93M
5
NXTC icon
NextCure
NXTC
+$2.62M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
2 Miscellaneous 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWAV
51
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-160,000
Closed -$4.79M
CBAY
52
DELISTED
Cymabay Therapeutics
CBAY
– –
-140,000
Closed -$717K
SBBP
53
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-490,000
Closed -$1.17M
THOR
54
DELISTED
Synthorx, Inc. Common Stock
THOR
– –
-180,000
Closed -$2.93M
VRML
55
DELISTED
Vermillion, Inc.
VRML
– –
-1,265,000
Closed -$661K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2019 Portfolio in Review

As of Q4 2019, Opaleye Management held 56 positions worth $510M, up 84% from $277M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management deployed $45.1M of net new capital in Q4 2019, opening 7 new positions and adding to 29 existing holdings. Its largest new stake was Achillion Pharmaceuticals: 760,000 shares worth $4.58M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Quanterix, an estimated $1.2M trimmed.

  • Opaleye Management's largest Q4 2019 buy was Achillion Pharmaceuticals: 760,000 shares worth $4.58M.
  • Opaleye Management added most to Aptose Biosciences, Inc. in Q4 2019, an estimated $9.74M increase.
  • Opaleye Management's biggest Q4 2019 reduction was Quanterix, cutting an estimated $1.2M.
  • Opaleye Management fully exited Tvardi Therapeutics in Q4 2019, selling an estimated $8.04M.
  • Opaleye Management's ten largest holdings make up 43% of its $510M portfolio in Q4 2019.
  • Opaleye Management opened 7 new positions and closed 9 in Q4 2019.
  • Opaleye Management's portfolio value rose 84% quarter-over-quarter to $510M.

Based on Opaleye Management's 13F filing for Q4 2019, filed 14 Feb 2020.